04 Oct 2021 by admin in UncategorizedComments NextCure Announces New Appointments to its Board of Directors
29 Sep 2021 by admin in UncategorizedComments Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute Promyelocytic Leukemia
28 Sep 2021 by admin in UncategorizedComments Syros Reports Inducement Grant to Chief Commercial Officer under Nasdaq Listing Rule 5635(c)(4)
27 Sep 2021 by admin in UncategorizedComments Syros Announces Appointment of Conley Chee as Chief Commercial Officer
20 Sep 2021 by admin in UncategorizedComments Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche
14 Sep 2021 by admin in UncategorizedComments Alebund Pharmaceuticals Raises $54.5 Million in Series B+ Financing Round to Fuel Development of Renal Disease Treatment
13 Sep 2021 by admin in UncategorizedComments Walking Fish Therapeutics Launches with $50 Million in Series A Financing to Accelerate Development of B Cell Therapies for Multiple Diseases
13 Sep 2021 by admin in UncategorizedComments Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target
13 Sep 2021 by admin in UncategorizedComments Adicet Bio Collaborates with Twist Bioscience to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics
10 Sep 2021 by admin in UncategorizedComments Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors
09 Sep 2021 by admin in UncategorizedComments Syros Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML
08 Sep 2021 by admin in UncategorizedComments Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1
16 Aug 2021 by admin in UncategorizedComments Innoforce Pharmaceuticals Opens Analytical Development and Process Development Facility in Hangzhou, China
12 Aug 2021 by admin in UncategorizedComments Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights
12 Aug 2021 by admin in UncategorizedComments Adicet Reports Second Quarter 2021 Financial Results and Provides Business Updates
09 Aug 2021 by admin in UncategorizedComments Tempest Announces Appointment of Ronit Simantov, M.D. to its Board of Directors
09 Aug 2021 by admin in UncategorizedComments Design Therapeutics Reports GeneTACTM Portfolio Progress and Second Quarter 2021 Results
05 Aug 2021 by admin in UncategorizedComments Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
05 Aug 2021 by admin in UncategorizedComments Syros Announces Agreement with Roche to Evaluate SY-5609 as Part of a Novel Combination for Treatment of Colorectal Cancer
20 Jul 2021 by admin in UncategorizedComments Eluminex Biosciences Expands Leadership Team and Receives Award
19 Jul 2021 by admin in UncategorizedComments Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform
15 Jul 2021 by admin in UncategorizedComments Adicet Bio Announces Formation of Scientific Advisory Board
09 Jul 2021 by admin in UncategorizedComments 日本中外制药(Chugai)与礼邦医药(Alebund)就 EOS789 开发用于高磷血症治疗达成期权/授权协议
06 Jul 2021 by admin in UncategorizedComments NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors
01 Jul 2021 by admin in UncategorizedComments Tempest Announces Appointment of Christine Pellizzari to its Board of Directors
28 Jun 2021 by admin in UncategorizedComments Tempest Closes Merger with Millendo and Completes PIPE Financing
22 Jun 2021 by admin in UncategorizedComments Tempest and Millendo Announce Stockholder Approval of Merger
21 Jun 2021 by admin in UncategorizedComments NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410
07 Jun 2021 by admin in UncategorizedComments Design Therapeutics Expands Board of Directors with Key Appointments
04 Jun 2021 by admin in UncategorizedComments Arcellx Announces Presentation of Positive Clinical Results from Ongoing Phase 1 Study of CART-ddBCMA at the 2021 ASCO Annual Meeting
20 May 2021 by admin in UncategorizedComments Crescendo Biologics announces initiation of Phase 1 study of CB307 in patients with advanced, PSMA-positive solid tumours
19 May 2021 by admin in UncategorizedComments NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
19 May 2021 by admin in UncategorizedComments Arcellx to Present Data from Phase 1 Study of CART-ddBCMA Demonstrating Continued Positive Response in Patients with Relapsed and Refractory Multiple Myeloma at the 2021 ASCO Annual Meeting
17 May 2021 by admin in UncategorizedComments Adicet Reports First Quarter 2021 Financial Results and Provides Business Updates
